Deaths / year
2,000
GBD (indicative unless refreshed)
DALYs / year
1,900,000
GBD
Pathogen
Helminth
Post-infectious
Chronic disease
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Chronic anaemia, malnutrition, growth & cognitive impairment (children)
Classification
Chronic disease
Onset
chronic morbidity
Persistent-symptom %
not quantified as a single figure (see notes)
Source: WHO STH fact sheet
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Sanitation & hygiene (WASH) | Prevention | Approved | Reduce soil contamination with infective eggs/larvae | WHO STH |
| Albendazole | Anthelmintic | Approved | Ascariasis, hookworm, trichuriasis MDA | WHO EML / standard of care |
| Mebendazole | Anthelmintic | Approved | Alternative benzimidazole | WHO EML / standard of care |
| MoxidectinPipeline | Anthelmintic | Phase 2 | Hookworm (investigational MDA) | Clinical trials |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Ivermectin | Anthelmintic | Approved | Strongyloides; combination MDA | WHO EML / standard of care |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Iron supplementation & nutritional rehab | Supportive | Approved | Chronic anaemia and growth impairment in children | WHO STH |
Associated drug targets (Open Targets): IGHE, CXCR3, IL10, CD40LG, CD79A, GSTM1
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0005654 · Updated 2026-07-10. Associations, not a diagnostic test.